A detailed history of Continuum Advisory, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Continuum Advisory, LLC holds 1,565 shares of VRTX stock, worth $638,801. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,565
Previous 1,681 6.9%
Holding current value
$638,801
Previous $787,000 7.62%
% of portfolio
0.09%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$460.0 - $505.78 $53,360 - $58,670
-116 Reduced 6.9%
1,565 $727,000
Q2 2024

Jul 19, 2024

BUY
$392.81 - $485.53 $27,889 - $34,472
71 Added 4.41%
1,681 $787,000
Q1 2024

May 10, 2024

BUY
$407.69 - $446.08 $109,668 - $119,995
269 Added 20.06%
1,610 $672,000
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $27,783 - $33,265
81 Added 6.43%
1,341 $545,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $32,127 - $34,433
95 Added 8.15%
1,260 $438,000
Q2 2023

Dec 13, 2023

SELL
$314.42 - $351.91 $13,205 - $14,780
-42 Reduced 3.48%
1,165 $409,000
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $13,205 - $14,780
-42 Reduced 3.48%
1,165 $409,000
Q1 2023

Dec 13, 2023

BUY
$283.23 - $323.1 $120,372 - $137,317
425 Added 54.35%
1,207 $380,000
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $120,372 - $137,317
425 Added 54.35%
1,207 $380,000
Q4 2022

Dec 13, 2023

SELL
$285.76 - $321.48 $7,429 - $8,358
-26 Reduced 3.22%
782 $225,000
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $7,429 - $8,358
-26 Reduced 3.22%
782 $225,000
Q3 2022

Dec 13, 2023

SELL
$273.83 - $305.53 $123,771 - $138,099
-452 Reduced 35.87%
808 $233,000
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $221,254 - $246,868
808 New
808 $234,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Continuum Advisory, LLC Portfolio

Follow Continuum Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continuum Advisory, LLC with notifications on news.